Back to Search
Start Over
[Front line of management of hyperphosphatemia in hemodialysis patients].
- Source :
-
Clinical calcium [Clin Calcium] 2004 May; Vol. 14 (5), pp. 771-7. - Publication Year :
- 2004
-
Abstract
- Management of hyperphosphatemia in hemodialysis patients is very important to prevent progress of renal hyperparathyroidism or ectopic calcification. Sevelamer hydrochloride is a Ca and Al free phosphate binder, and reduces serum phosphorus level, without any influence on serum Ca level, and Ca-P products. This compound is expected to reduce the incidence of arterial calcification, and improve the QOL (quality of life) of hemodialysis patients.
- Subjects :
- Calcinosis etiology
Calcinosis prevention & control
Calcium blood
Humans
Hyperparathyroidism, Secondary etiology
Hyperparathyroidism, Secondary prevention & control
Kidney Failure, Chronic complications
Phosphorus Metabolism Disorders etiology
Polyamines
Sevelamer
Vascular Diseases etiology
Vascular Diseases prevention & control
Epoxy Compounds therapeutic use
Ion Exchange Resins therapeutic use
Phosphorus blood
Phosphorus Metabolism Disorders drug therapy
Polyethylenes therapeutic use
Renal Dialysis adverse effects
Subjects
Details
- Language :
- Japanese
- ISSN :
- 0917-5857
- Volume :
- 14
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- Clinical calcium
- Publication Type :
- Academic Journal
- Accession number :
- 15577041
- Full Text :
- https://doi.org/CliCa04057771777